Cancer is predicted to remain a leading cause of death in the U.S., and cost of care for the disease could exceed $240 billion by 2030 — so it's no wonder that preventative measures and early detection are top-of-mind for leaders across the healthcare industry. To change the trajectory, many are looking to the latest innovations in oncology, including multi-cancer early detection screening.
Join this live session to learn how Canton, Mass.-based Point32Health piloted this testing method and the positive engagement from patients.
You'll also learn about:
- The unmet need in cancer screening, specifically for cancer types with no current screening standards
- Techniques used in multi-cancer early detection tests to find and identify potential cancer signals
- Current research on consumer perception + interest in multi-cancer early detection tests, as well as market research on the impact of these tests when offered as a supplemental benefit in Medicare Advantage plans
.png?width=120&height=119&name=Joe%20McKenna%20Headshot%20(1).png)
%20(1).jpeg?width=120&height=120&name=Prof%20Pic%20Headshot%20(1)%20(1).jpeg)